Aurora kinase A (AURKA) promotes the progression and imatinib resistance of advanced gastrointestinal stromal tumors
Abstract Background Gastrointestinal stromal tumor (GIST) is a common tumor that originates from the alimentary system mesenchyme. Compared to typical gastrointestinal carcinomas, GISTs exhibit unique malignant behaviors. Bioinformatic tools and subsequent experiments were applied to investigate nov...
Main Authors: | Xiaobin Cheng, Jinhai Wang, Sen Lu, Weina Fan, Weilin Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-07-01
|
Series: | Cancer Cell International |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12935-021-02111-7 |
Similar Items
-
Safety of Regular-Dose Imatinib Therapy in Patients with Gastrointestinal Stromal Tumors Undergoing Dialysis
by: Ryota Niikura, et al.
Published: (2016-05-01) -
Imatinib Mesylate Therapy in Advanced Gastrointestinal Stromal Tumors: Experience from a Single Institute
by: Hui-Hua Hsiao, et al.
Published: (2006-12-01) -
Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
by: Sumin Tang, et al.
Published: (2017-04-01) -
Effect of the imatinib treatment regimen on the postoperative prognosis of patients with high-risk gastrointestinal stromal tumors
by: Li YS, et al.
Published: (2019-06-01) -
Imatinib-Resistant Gastrointestinal Stromal Tumor Presenting as a Large Abdominal Mass
by: Asim Haider, et al.
Published: (2021-08-01)